Tuesday, 30 October, 2018

FierceBiotech Executive Summit: London

1 Wimpole Street - Home of The Royal Society of Medicine | London

About

In a post-Brexit world, what is the U.K. doing to remain competitive in biomedical science?

As the U.K. approaches a future outside of the Europe Union, we look at the infrastructures of biomedical science in U.K. and the challenges and opportunities to boosting life sciences amid a time of major change.

We will speak to key leaders from across life sciences in the U.K., including MedCity, the Cell and Gene Therapy Catapult and the Francis Crick Institute in London about the work they are undertaking, and how they are planning for Brexit in terms of funding, staffing and any impact to longer term projects, as well as what opportunities may lay ahead post-Brexit.

We will also look at a burgeoning new digital health industry. According to Deloitte, the U.K.’s digital health market is set to hit £2.9bn this year, predominately driven by mHealth apps. We take a look at how the NHS and biopharma are incorporating social media, apps, big data and the rise of ePatients, and this can help research. 

Speakers

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Steve Bates

CEO // BioIndustry Association
Since his appointment as Chief Executive of the BioIndustry Association in 2012, Steve has led major BIA campaigns for, amongst other things, improved access to finance, the refilling of the Biomedical Catalyst, anti-microbial resistance and the opportunity the sector presents to generalist long term investors. Steve champions the adaptive pathway approach to the licensing of new drugs, the need for Early Access and is particularly proud of the working relationship the BIA has established with the UK’s leading medical research charities.

A founder member of United Life Sciences, a strategic partnership representing over 1000 life science and healthcare member companies across the UK and internationally, Steve attends the UK’s Ministerial Industry Strategy Group, and sits on The Royal Society's Science, Industry and Translation Committee.

Beyond the UK Steve is a member of EuropaBio’s Board and its National Association Council and is a founder member of the International Confederation of Biotech Associations. An expert and regular commentator on the sector in the media and at industry-leading conferences Steve has worked both in biotech (as Senior Director at Genzyme UK and Ireland) and at the highest levels of UK government (as Special Advisor to John Reid, MP, during his time in Tony Blair’s government) for over 15 years. Steve was awarded the OBE in January 2017.

Dr. Munna Choudhury

Independent Consultant // Affiliated with Accenture and Alacramed
Munna is a Management Consultant with 13+ years experience in the Health & Life Sciences Strategy practice at Accenture where she managed engagements with pharmaceutical, biotech and medical device companies globally.

Munna has specific expertise in pharmaceutical R&D, maximizing value from the drug discovery & development process and the broader healthcare landscape.

She is author of several papers addressing key issues in Pharma/Medical Device R&D; has presented extensively at Orthopaedic Research Society conferences (USA) and academic conferences linked to Regenerative Medicine & Precision Health.
PhD, MA (Cantab) and BA (Hons) in Natural Sciences from the University of Cambridge, UK.


Dr. Chris Doherty

Managing Director // Alderley Park
Chris heads up Alderley Park, one of the UK’s largest bioscience sites, which is now home to 61 SMEs and over 150 start-ups.  Chris graduated as a Pharmacist completing a PhD in pharmaceutical technology and a MBA a few years later. He has depth experience in major pharmaceutical companies, including AstraZeneca, Roche and Glaxo covering 26 years in multiple roles with over 10 years at senior executive level. Alderley Park itself has been the subject of a large scale investment programme by its owner Bruntwood, which has added laboratory space and other facilities at the site, which is located in 400 acres of parkland in Cheshire. 

Matthew Durdy (High Honors), MA (Oxon.), FCSI

Chief Business Officer // Cell and Gene Therapy Catapult
Part of the team that created the Catapult, he is also an Executive Director. He is responsible for strategy, and finding, funding and transacting the business of the Catapult.

He has been a champion of the early integration of healthcare economics and reimbursement expertise into decision- making and clinical product design in the sector. He began his career in international investment banking and has successfully managed a number of biotechnology SMEs. His first degree was from Oxford University in Biology and he has an MBA (High Honors) from Chicago Booth. He is a non-executive director of an immune-oncology company and periodically assists the UK Government and international organisations in the development of initiatives in healthcare innovation.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Dr. Peter Jackson

Executive Director // The AMR Centre
Dr Peter Jackson is Executive Director of the AMR Centre – a UK public-private partnership focused on antimicrobial resistance R&D, and an alliance member of the transatlantic CARB-X initiative. An experienced life sciences entrepreneur, Dr Jackson is the founder of six life sciences ventures over the past 10 years. Before that, he had over 15 years in the sector, previously holding senior executive roles as a Commercial Director and then head of Avecia’s Pharmaceutical Products business unit, following senior commercial and R&D positions at Zeneca and ICI. Dr Jackson was also a founder director of the National Skills Academy for Process Industries.

Tony Jones (Opening Remarks)

CEO // One Nucleus
Tony undertook several years of post-doctoral research in the oncology field prior to moving into Technology Transfer in 1997. He was Director of the London Biotechnology Network from 2003 before leading its merger into ERBI in 2010, creating One Nucleus. Tony became CEO of One Nucleus in 2017 in order to lead the organisation through its next stage of development.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

John has over 15 years’ experience in building and leading biotech companies across discovery, development, financing and business development. He successfully managed several monoclonal, oligoclonal, and bispecific antibody products into clinical development, as well as managed and developed numerous collaborations with biopharmaceutical companies in the US, Europe, and Japan. Prior to joining F-star, John was VP Research, Biologics Products at ImClone Systems, a wholly-owned subsidiary of Eli Lilly and Company. Previously, he was a cofounder and Chief Scientific Officer of Symphogen A/S, a Danish biotechnology company developing therapeutic antibody combinations. John holds an MD from University of Aarhus, Denmark and a D.Phil. in Immunology from the Institute of Molecular Medicine, University of Oxford, UK.

FirstName LastName

Job Title
Lorem ipsum dolor sit amet, consectetur adipisicing elit. Excepturi corrupti dolor vel enim facere ratione quos aliquam, quam repellat maiores laboriosam eligendi minus cum illum dolorem iure itaque. Tenetur, maxime! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Laborum a laudantium veniam dignissimos animi totam. Veniam eaque laborum adipisci minima eveniet, hic sed iste amet, nulla modi, voluptatibus possimus tempora. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Optio quisquam placeat aut repudiandae eveniet sequi quas dolore veritatis corrupti inventore, voluptatem voluptatum magnam alias facere laborum doloribus at, repellat libero. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Perferendis qui quod fugit labore, laboriosam voluptate asperiores. Laudantium quo, exercitationem tenetur delectus autem totam, aliquid quam repellat quaerat reprehenderit aliquam architecto. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Suscipit voluptatum nihil voluptatibus harum, neque ex ducimus aliquid sit quas iusto eligendi. Rem suscipit dolore nam dignissimos repudiandae omnis exercitationem, vel. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Voluptatem, deserunt. Minima, eveniet quis pariatur aliquam veniam saepe, et magnam perferendis molestias eligendi vel ex animi consectetur nam repellendus. Doloremque, nulla! Lorem ipsum dolor sit amet, consectetur adipisicing elit. Ad dolore, distinctio eveniet vero autem tempora molestiae dolor eos voluptatem fuga reiciendis harum soluta quos nemo! Soluta veritatis ab magnam reiciendis. Lorem ipsum dolor sit amet, consectetur adipisicing elit. Cumque debitis quae nihil minima dolores itaque labore, repudiandae beatae nemo consequatur? Accusantium, eveniet possimus soluta repellat dicta quam fugit excepturi, voluptatibus!

Peter Pack has 24 years of experience in the successful establishment and growth of international life science companies. For 16 years, he was CEO and Managing Director of product-oriented companies ranging from early stage up to international commercialization and profitability with several thousand certified products; predominantly working in Germany, the UK and Poland. He raised over € 54 m in venture capital, worked on several Boards and headed companies with up to 400 employees.

He started his career in the initial team of MorphoSys AG (1993-1999) as co-inventor of the commercially most successful phage library and was co-founder and CEO of the cancer diagnostics company mtm laboratories (1999-2008). The companies for which Peter worked in central positions were either successfully sold (mtm laboratories, Polytech Ophthalmologie, Signature Diagnostics), highly profitable (LGC Standards, Polytech) and/or went public (MorphoSys AG).

Ben Adams (Moderator)

Senior Editor
FierceBiotech
Ben Adams is a business, science and healthcare journalist who has worked as an editor for the UK publication Pharmafocus and as a group editor Pharmaceutical Marketing Europe, as well as a features and news writer for the BMJ and the Pharmaceutical Journal. He has an especial interest in market access, drug pricing and the ethics of the life sciences industry and has been heavily involved in ensuring the need for greater clinical study transparency remains on the agenda for the industry. On the personal side, he enjoys reading esoteric pieces of literary fiction from Charles Williams, Will Self, Ros Barber and Milan Kundera, and is currently awaiting the publication of his own set of literary juvenilia, coming to a second-hand bookshop no-where near anyone soon. Ben is based on the south coast of England and can be reached at [email protected]

Carly Helfand (Moderator)

Senior Editor
FiercePharma
Carly Helfand is a news editor with FierceMarkets' Life Sciences group, writing for FierceVaccines, FiercePharma and FiercePharmaMarketing. Carly got her start covering pharma while earning her master's at Northwestern University's Medill School of Journalism, where she concentrated in business reporting. She has completed journalism projects on four continents, and her work has appeared in various outlets such as The Boston Globe, The Washington Post's Wonkblog and Cape Town's Weekend Argus. Carly prefers watching pro hockey to nearly everything. She also plays the Irish fiddle. You can contact her at [email protected]

schedule

13:00 - 13:45: Registration and Networking

13:45 - 14:00: Introduction and Opening Remarks

14:00 - 15:30: Panel // Challenges and Opportunities for Life Science Post-Brexit

15:30 - 16:00: Coffee Break

16:00 - 17:00: Fireside Chat

17:00 - 18:30: Reception and Networking

Agenda

Challenges and Opportunities for Life Science Post-Brexit
14:00 - 15:30


How well is the U.K. set up to deal with Brexit over the next 10 years – what are the challenges and opportunities to British life sciences? How well do the corporate, academic and charitable biomedical infrastructures work in the U.K., and what are they doing to prepare for Brexit?


Speakers

FirstName LastName

Job Title

Dr. Munna Choudhury

Independent Consultant // Affiliated with Accenture and Alacramed

Dr. Chris Doherty

Managing Director // Alderley Park

Matthew Durdy (High Honors), MA (Oxon.), FCSI

Chief Business Officer //
Cell and Gene Therapy Catapult

Dr. Peter Jackson

Executive Director // The AMR Centre

Carly Helfand (Moderator)

Senior Editor // FiercePharma

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title
Fireside Chat
15:20 - 16:10
FierceBiotech Senior Editor, Ben Adams, sits down with BIA CEO, Steve Bates, to discuss the biotech view of Brexit; what the government is doing to to help life science R&D and venture capital flows, and the health of U.K. biotech as we prepare to leave the Europe Union. 

Speakers

Steve Bates

CEO // BioIndustry Association

Ben Adams (Moderator)

Senior Editor // FierceBiotech

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

FirstName LastName

Job Title

sponsors

Pricing

Standard Registration

£260 per person (Approximately $300)

Register now!

*Please note that the fees to attend this event will be charged in US Dollars and the amount is dependent upon the currency exchange rate at the time of registration.

location

FAQ

There is not a dedicated parking lot for the Royal Society of Medicine, and street parking is very limited. It is suggested that attendees arrive via public transportation or taxi. 

Yes, light refreshments will be served in the afternoon. Attendees are also invited to stay after the presentations for a cocktail reception.

Yes, wi-fi will be available.